Skip to main content

Table 1 Patients in high-risk subgroup categories (CE population)

From: Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

CAP HAP (excluding VAP)
Baseline risk factor Ceftobiprole Ceftriaxone ± linezolid Baseline risk factor Ceftobiprole Ceftazidime plus linezolid
Any risk factor 193 205 Any risk factor 169 138
PORT ≥ III 126 117 APACHE score ≥ 15 67 59
PORT ≥ IV 51 58 >10 comorbidities 63 61
Sepsis 123 135 Mechanical ventilationa 38 37
Bacteraemiab 7 14 Bacteraemiab 15 11
Age ≥ 75 years 39 50 Age ≥ 75 years 59 54
COPD 51 59 COPD 55 39
ICU 25 26 ICU 73 59
  1. aMechanical ventilation at baseline or at any point during the study
  2. bFurther analyses were not conducted in the bacteraemia group as the number of patients in both treatment arms was below 20
  3. APACHE Acute Physiology and Chronic Health Evaluation, CAP community-acquired pneumonia, CE clinically evaluable, COPD chronic obstructive pulmonary disease, HAP hospital-acquired pneumonia, ICU intensive care unit, PORT Patient Outcome Research Team, VAP ventilator-associated pneumonia